Pacer Advisors Inc. Sells 818,721 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Pacer Advisors Inc. reduced its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 24.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,589,648 shares of the specialty pharmaceutical company's stock after selling 818,721 shares during the quarter. Pacer Advisors Inc. owned 8.04% of Collegium Pharmaceutical worth $100,064,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Gladius Capital Management LP bought a new position in Collegium Pharmaceutical in the 2nd quarter valued at approximately $32,000. nVerses Capital LLC raised its stake in Collegium Pharmaceutical by 1,600.0% during the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company's stock worth $55,000 after buying an additional 1,600 shares during the period. GAMMA Investing LLC grew its stake in Collegium Pharmaceutical by 124.5% in the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company's stock valued at $55,000 after acquiring an additional 792 shares during the period. CWM LLC raised its holdings in Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company's stock worth $58,000 after buying an additional 736 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC acquired a new stake in shares of Collegium Pharmaceutical in the 1st quarter worth about $204,000.

Collegium Pharmaceutical Trading Down 1.5 %

Shares of Collegium Pharmaceutical stock traded down $0.45 on Friday, hitting $29.96. The stock had a trading volume of 394,149 shares, compared to its average volume of 445,963. The stock's 50-day simple moving average is $35.84 and its two-hundred day simple moving average is $34.82. Collegium Pharmaceutical, Inc. has a one year low of $25.16 and a one year high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The stock has a market cap of $966.21 million, a price-to-earnings ratio of 12.88 and a beta of 0.95.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the transaction, the executive vice president now owns 120,161 shares in the company, valued at approximately $4,602,166.30. The trade was a 13.81 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the transaction, the executive vice president now directly owns 53,816 shares of the company's stock, valued at $1,970,741.92. This trade represents a 15.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 3.98% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Truist Financial upped their price objective on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a "buy" rating in a research report on Friday, August 9th. StockNews.com cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, October 23rd. Piper Sandler reaffirmed a "neutral" rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 11th. HC Wainwright raised their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a "buy" rating in a research note on Thursday, September 5th. Finally, Needham & Company LLC restated a "hold" rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Collegium Pharmaceutical presently has an average rating of "Moderate Buy" and an average price target of $42.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.